Fig. 1: Identification of the non-cytotoxic concentration of ZLDI-8 in MHCC97-H cells. | Cell Death & Disease

Fig. 1: Identification of the non-cytotoxic concentration of ZLDI-8 in MHCC97-H cells.

From: Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells

Fig. 1

a Molecular docking for the interaction between ZLDI-8 and ADAM-17. b MHCC97-H cells were treated with indicated concentration of ZLDI-8, and the inhibition rates were calculated. c The effect of 1 μmol/L or 3 μmol/L ZLDI-8 was examined at each time point. d MHCC97-H, which were treated with indicated concentration of ZLDI-8, were fractionated into cytoplasmic and nuclear fractions. The fractions were detected with anti-NICD antibody and ADAM-17 antibodies. β-actin was chosen as a cytoplasmic marker and Lamin A/C was the nuclear indicator. e, f MHCC97-H cells, which were treated with 1 μmol/L ZLDI-8, were examined to detect the protein level of anti-apoptosis/pro-survival (e) or EMT (f) related regulators

Back to article page